Ozempic for Alzheimer’s?

If you’ve had patients ask whether their weight-loss injection might also protect them from dementia, you’re not alone. Recent observational data has linked GLP-1 RAs to a lower risk of Alzheimer’s. This information has been in mainstream media for over a year, and some findings seemed quite promising. A large retrospective study found that semaglutide cut Alzheimer’s risk by 67% compared to insulin. It also lowered the risk by 41% compared to other GLP-1 RAs. Pre-clinical models showed neuroprotective effects through anti-inflammatory and vascular pathways.

Novo Nordisk took the hypothesis seriously and ran two large Phase 3 trials to find out. The results were first reported in November 2025. They were fully presented at the AD/PD 2026 conference in Copenhagen on 19 March. These findings are definitive.

EVOKE and EVOKE+ enrolled 3,808 adults aged 55 to 85. These participants had mild cognitive impairment (MCI) or mild Alzheimer’s disease dementia, and they tested positive for amyloid. This took place across nearly 40 countries. Participants were randomised to oral semaglutide 14 mg daily or placebo for 104 weeks, on top of standard care (including approved Alzheimer’s medications).

On the primary endpoint, change in Clinical Dementia Rating Sum of Boxes (CDR-SB) at two years, there was no difference between semaglutide and placebo. Not a small effect that missed significance. No drug-placebo difference at all. The same was true for every secondary endpoint: activities of daily living, Mini-Mental State Examination (MMSE), and Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). A pooled analysis found no difference in progression from MCI to mild Alzheimer’s. Subgroup analyses by sex, age, body mass index (BMI), and diabetes status showed no signal of benefit in any group.

There was one positive finding. Semaglutide lowered peripheral inflammatory markers significantly. C-reactive protein (CRP) fell by about 30%. It also caused modest reductions of around 10% in cerebrospinal fluid (CSF) biomarkers linked to Alzheimer’s. The investigators and independent commentators agree: these biomarker changes were too small to lead to clinical benefits, and they didn't.

The principal investigator, Jeffrey Cummings, has been candid about what this means. Semaglutide does not substantially enter the brain. It reduced peripheral inflammation effectively, but that was not enough to alter the course of a central nervous system disease. The finding doesn’t rule out brain-penetrant GLP-1 RAs or anti-inflammatory drugs. But, it does eliminate semaglutide for this use. Novo Nordisk has terminated the programme and discontinued the planned one-year extension of both trials.

These results have not yet been published in a peer-reviewed journal. Full publication is expected but at the time of writing, the data is from conference presentations only. The trial design paper is available in Alzheimer’s Research & Therapy.

For primary care, the practical takeaway is straightforward. GLP-1 RAs remain important medicines for type 2 diabetes and obesity. But if a patient asks whether their semaglutide might help with cognitive decline or dementia risk, the answer based on the best available evidence is that it does not. The observational associations were real, but they did not survive the scrutiny of a well-designed randomised trial.

References

Medicine Central is a clinical evidence review for UK primary care clinicians. Content reflects evidence current at time of publication and should be read alongside local formulary and clinical guidance. For healthcare professionals only.